BACKGROUND: The optimal treatment of patients with chronic hepatitis B (CHB) who develop resistance to both lamivudine (LMV) and entecavir (ETV) after sequential monotherapy of LMV and ETV remains little known. METHODS: We evaluated the efficacy of entecavir (ETV) plus adefovir dipivoxil (ADV) combination therapy for patients with resistance to LMV and ETV. We reviewed the medical records of 12 patients, and treated all 12 patients with ETV plus ADV combination therapy for at least 18 months. Quantitative hepatitis B virus (HBV) DNA levels, serologic markers, and hepatic panel values were monitored at baseline and 3-month intervals thereafter for 18 months. RESULTS: The baseline mean serum HBV DNA level was 7.26 ± 1.11 log(10) copies/ml. The mean reductions in serum HBV DNA levels from baseline to 3, 6, 9, 12, 15, and 18 months were -1.98 ± 1.03, -2.87 ± 1.02, -3.32 ± 1.10, -3.92 ± 1.30, -4.36 ± 1.22, and -4.57 ± 1.18 log(10) copies/ml, respectively. Complete virological response (HBV DNA of <2 log(10) copies/ml) at 6, 12, and 18 months was observed in 1 (8.3%), 4 (33.3%), and 6 (50.0%) patients, respectively. The 2 patients with baseline HBV DNA of <6 log(10) copies/ml achieved complete virological response at 18 months, while 4 of 10 patients with baseline HBV DNA of ≥6 log(10) copies/ml achieved complete virological response at 18 months. None of the 12 patients experienced virological breakthrough during follow-up. CONCLUSIONS: ETV plus ADV combination therapy effectively reduced serum HBV DNA levels in patients with CHB who developed resistance to both LMV and ETV. Additional long-term studies are needed to assess the effect of long-term treatment with these drugs.
BACKGROUND: The optimal treatment of patients with chronic hepatitis B (CHB) who develop resistance to both lamivudine (LMV) and entecavir (ETV) after sequential monotherapy of LMV and ETV remains little known. METHODS: We evaluated the efficacy of entecavir (ETV) plus adefovir dipivoxil (ADV) combination therapy for patients with resistance to LMV and ETV. We reviewed the medical records of 12 patients, and treated all 12 patients with ETV plus ADV combination therapy for at least 18 months. Quantitative hepatitis B virus (HBV) DNA levels, serologic markers, and hepatic panel values were monitored at baseline and 3-month intervals thereafter for 18 months. RESULTS: The baseline mean serum HBV DNA level was 7.26 ± 1.11 log(10) copies/ml. The mean reductions in serum HBV DNA levels from baseline to 3, 6, 9, 12, 15, and 18 months were -1.98 ± 1.03, -2.87 ± 1.02, -3.32 ± 1.10, -3.92 ± 1.30, -4.36 ± 1.22, and -4.57 ± 1.18 log(10) copies/ml, respectively. Complete virological response (HBV DNA of <2 log(10) copies/ml) at 6, 12, and 18 months was observed in 1 (8.3%), 4 (33.3%), and 6 (50.0%) patients, respectively. The 2 patients with baseline HBV DNA of <6 log(10) copies/ml achieved complete virological response at 18 months, while 4 of 10 patients with baseline HBV DNA of ≥6 log(10) copies/ml achieved complete virological response at 18 months. None of the 12 patients experienced virological breakthrough during follow-up. CONCLUSIONS:ETV plus ADV combination therapy effectively reduced serum HBV DNA levels in patients with CHB who developed resistance to both LMV and ETV. Additional long-term studies are needed to assess the effect of long-term treatment with these drugs.
Authors: S J Patterson; J George; S I Strasser; A U Lee; W Sievert; A J Nicoll; P V Desmond; S K Roberts; S Locarnini; S Bowden; P W Angus Journal: Gut Date: 2010-10-29 Impact factor: 23.059
Authors: Yoon-Seon Lee; Dong Jin Suh; Young-Suk Lim; Suk Won Jung; Kang Mo Kim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee; Wangdon Yoo; Soo-Ok Kim Journal: Hepatology Date: 2006-06 Impact factor: 17.425
Authors: Emmet B Keeffe; Douglas T Dieterich; Steven-Huy B Han; Ira M Jacobson; Paul Martin; Eugene R Schiff; Hillel Tobias Journal: Clin Gastroenterol Hepatol Date: 2008-08-23 Impact factor: 11.382
Authors: Eugene R Schiff; Ching-Lung Lai; Stefanos Hadziyannis; Peter Neuhaus; Norah Terrault; Massimo Colombo; Hans L Tillmann; Didier Samuel; Stefan Zeuzem; Leslie Lilly; Maria Rendina; Jean-Pierre Villeneuve; Nicole Lama; Craig James; Michael S Wulfsohn; Hamid Namini; Christopher Westland; Shelly Xiong; Gavin S Choy; Sally Van Doren; John Fry; Carol L Brosgart Journal: Hepatology Date: 2003-12 Impact factor: 17.425
Authors: Hyoung Su Kim; Hyung Joon Yim; Myoung Kuk Jang; Ji Won Park; Sang Jun Suh; Yeon Seok Seo; Ji Hoon Kim; Bo Hyun Kim; Sang Jong Park; Sae Hwan Lee; Sang Gyune Kim; Young Seok Kim; Jung Il Lee; Jin-Woo Lee; In Hee Kim; Tae Yeob Kim; Jin-Wook Kim; Sook-Hyang Jeong; Young Kul Jung; Hana Park; Seong Gyu Hwang Journal: World J Gastroenterol Date: 2015-10-14 Impact factor: 5.742